News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|August 16, 2024

Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib

Author(s)Ted Lain, MD, MBA, FAAD

Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo.

Episodes in this series

EP. 1 Insights into Navigating the Emotional and Clinical Challenges in Vitiligo Management

EP. 1 Insights into Navigating the Emotional and Clinical Challenges in Vitiligo Management

EP. 2 Balancing Vitiligo Treatments with Coverage Challenges

EP. 2 Balancing Vitiligo Treatments with Coverage Challenges

EP. 3 Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

EP. 3 Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

EP. 4 Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib

EP. 4 Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

A New Perspective on Seborrheic Dermatitis Management

ByMarie Bosslett, Assistant Editor

September 11th 2025

How to Individualize Biologic Therapy in Severe Prurigo Nodularis

ByKaitlyn Bader, Assistant Managing Editor

August 27th 2025

1 expert in this video

Importance of Shared Decision-Making and Tailored Treatment in Psoriasis Care

ByOmar Noor, MD, FAAD

August 6th 2025

1 expert in this video

Involving the Patient in Their Psoriasis Treatment With a 42-Year-Old Woman With a Busy Lifestyle

ByOmar Noor, MD, FAAD

August 6th 2025

1 expert in this video

Incorporating Patient Lifestyle into Treatment Decisions in a 64-Year-Old Man with Late-Onset Psoriasis

ByOmar Noor, MD, FAAD

August 6th 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Transformative Advances This Year and Beyond

FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol

Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control

"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

© 2025 MJH Life Sciences^®

All rights reserved.